Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) EBIT: 2018-2024

Historic EBIT for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to -$378.9 million.

  • Avidity Biosciences' EBIT fell 92.40% to -$188.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$612.5 million, marking a year-over-year decrease of 88.63%. This contributed to the annual value of -$378.9 million for FY2024, which is 60.84% down from last year.
  • Avidity Biosciences' EBIT amounted to -$378.9 million in FY2024, which was down 60.84% from -$235.6 million recorded in FY2023.
  • In the past 5 years, Avidity Biosciences' EBIT registered a high of -$44.3 million during FY2020, and its lowest value of -$378.9 million during FY2024.
  • For the 3-year period, Avidity Biosciences' EBIT averaged around -$264.5 million, with its median value being -$235.6 million (2023).
  • Data for Avidity Biosciences' EBIT shows a maximum YoY slumped of 166.62% (in 2021) over the last 5 years.
  • Avidity Biosciences' EBIT (Yearly) stood at -$44.3 million in 2020, then crashed by 166.62% to -$118.1 million in 2021, then plummeted by 51.56% to -$178.9 million in 2022, then crashed by 31.68% to -$235.6 million in 2023, then plummeted by 60.84% to -$378.9 million in 2024.